dc.contributor.author |
Siu Joey |
|
dc.contributor.author |
Klingler Lilian |
|
dc.contributor.author |
Wang Yi |
|
dc.contributor.author |
Hung Cheung-Tak |
|
dc.contributor.author |
Jeong Soo Hee |
|
dc.contributor.author |
Smith Susan |
|
dc.contributor.author |
Tingle Malcolm Drummond |
|
dc.contributor.author |
Wagner Mackenzie Brett |
|
dc.contributor.author |
Biswas Kristi |
|
dc.contributor.author |
Douglas Richard George |
|
dc.date.accessioned |
2020-11-12T04:00:45Z |
|
dc.date.available |
2020-11-12T04:00:45Z |
|
dc.date.issued |
2020-9-4 |
|
dc.identifier.issn |
0049-8254 |
|
dc.identifier.uri |
http://hdl.handle.net/2292/53584 |
|
dc.description.abstract |
Despite the widespread prescription of antibiotics for patients with chronic rhinosinusitis (CRS), the extent to which drug distribution to the sinonasal mucosa occurs remains largely undefined. Twenty subjects undergoing functional endoscopic sinus surgery (FESS) for CRS were randomized to one of two groups: 1) doxycycline (100 mg daily for seven days) 2) roxithromycin (300 mg daily for seven days). Drug levels were measured using liquid chromatography-tandem mass spectrometry in sinonasal mucus, sinonasal tissues and serum at steady state. Doxycycline concentrations measured in the mucus were significantly lower compared to that in the serum (mean mucus/serum ratio = 0.16, p < 0.001) and the tissue (mean mucus/tissue ratio = 0.18, p < 0.0001). Roxithromycin concentrations in the mucus were also significantly lower compared to that in the serum (mean mucus/serum ratio = 0.37, p = 0.002) and the tissue (mean mucus/tissue ratio = 0.60, p < 0.001). Although the efficacy of doxycycline and roxithromycin in sinonasal mucus in vivo cannot be predicted solely from reported minimum inhibitory concentrations, given the added complexity of bacterial biofilm antimicrobial tolerance, these results suggest that low mucosal penetration of antibiotics may be one of the factors contributing to the limited efficacy of these agents in the treatment of CRS. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
TAYLOR & FRANCIS LTD |
|
dc.relation.ispartofseries |
Xenobiotica; the fate of foreign compounds in biological systems |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
Clinical |
|
dc.subject |
Clinical Medicine and Science |
|
dc.subject |
Clinical Research |
|
dc.subject |
6.1 Pharmaceuticals |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Pharmacology & Pharmacy |
|
dc.subject |
Toxicology |
|
dc.subject |
Sinusitis |
|
dc.subject |
Bacteria |
|
dc.subject |
Microbiota |
|
dc.subject |
Antibiotics |
|
dc.subject |
Antibiotic resistance |
|
dc.subject |
Macrolides |
|
dc.subject |
Tetracyclines |
|
dc.subject |
PHARMACOKINETICS |
|
dc.subject |
RESISTANCE |
|
dc.subject |
0601 Biochemistry And Cell Biology |
|
dc.subject |
1115 Pharmacology And Pharmaceutical Sciences |
|
dc.title |
Oral antibiotics used in the treatment of chronic rhinosinusitis have limited penetration into the sinonasal mucosa: a randomized trial. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1080/00498254.2020.1814973 |
|
pubs.begin-page |
1 |
|
dc.date.updated |
2020-10-27T20:32:39Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000566671000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d |
|
pubs.end-page |
8 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
815999 |
|
dc.identifier.eissn |
1366-5928 |
|